logo
FDA urges Elevidys to pause after third death; Sarepta refuses

FDA urges Elevidys to pause after third death; Sarepta refuses

Canada News.Net21-07-2025
CAMBRIDGE, Massachusetts: A third patient death linked to gene therapy technology has intensified scrutiny on Sarepta Therapeutics, whose Duchenne muscular dystrophy treatment, Elevidys, remains at the centre of safety concerns.
Despite a request from U.S. regulators to halt shipments, the company is refusing to pause deliveries for ambulatory patients.
On July 18, the Food and Drug Administration confirmed that it had asked Sarepta to voluntarily stop distributing Elevidys, a gene therapy for Duchenne muscular dystrophy. The request came during a meeting between the agency and the company.
Sarepta declined the FDA's request, stating it would continue shipping Elevidys to patients who are able to walk while maintaining an existing pause for non-ambulatory patients — a halt implemented by the company on June 15 after reporting a case of acute liver failure.
Sarepta said its decision to continue shipping to ambulatory patients was "based on our comprehensive scientific interpretation of the data, which shows no new or changed safety signals in the ambulant patient population."
The most recent patient death — a 51-year-old man with limb girdle muscular dystrophy — did not involve Elevidys but another experimental therapy using similar gene technology. The FDA said clinical trials involving limb girdle muscular dystrophy have now been placed on hold due to safety concerns.
Earlier this year, two teenage boys receiving Elevidys died of acute liver failure. All three deaths occurred in non-ambulatory patients. These events have raised alarm among regulators, investors, and patient advocacy groups.
Elevidys received traditional FDA approval in 2024 for ambulatory patients aged four and older with Duchenne muscular dystrophy. It was also granted accelerated approval for non-ambulatory patients, despite the therapy failing to meet its primary goal in a late-stage trial.
In a further regulatory setback, the FDA also revoked Sarepta's platform technology designation for its AAVrh74 gene therapy — a status that would have streamlined approval for similar treatments.
Following the news of the third death and the regulatory developments, Sarepta shares plunged 36 percent on July 18 to US$14.08, briefly hitting a more than nine-year low.
The FDA is continuing to investigate the risk of acute liver failure linked to Sarepta's platform technology. Some analysts have said this could make patients and families more reluctant to consider the therapy.
"Families with Duchenne muscular dystrophy are grappling with a mix of disappointment, concern... and uncertainty about choices they are making for their children or themselves," said Debra Miller, founder of the non-profit CureDuchenne.
Sarepta said earlier this week that it is working with the FDA to update Elevidys' packaging to include a warning about liver toxicity risks.
However, the company is also facing criticism for its communication handling. During an investor call, analysts questioned why Sarepta had not disclosed the latest patient death earlier in the week when it announced 500 layoffs and financial restructuring. CEO Doug Ingram responded that the death was "neither material nor central" to that announcement.
Some analysts, including those at BMO Capital Markets, have warned that how the disclosure was managed could damage Sarepta's credibility with investors.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia

National Post

time13 hours ago

  • National Post

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia

Article content Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies Article content SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor. Article content 'This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced interaction with the EMA as we advance BGB-16673,' said Julie Lepin, Senior Vice President, Chief Regulatory Affairs Officer at BeOne. 'PRIME allows us to align early with the EMA on key evidence requirements and potentially accelerate our path to marketing authorization of BGB-16673 for patients with relapsed or refractory Waldenstrom's macroglobulinemia.' Article content In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM. A final decision is anticipated in the coming weeks. The U.S. Food and Drug Administration (FDA) also granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Article content The EMA's CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. The CHMP recognized the limited treatment options available for WM patients post-BTK inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting, thereby demonstrating the potential to address the unmet medical need. Article content The PRIME initiative, launched by the EMA in 2016, provides early, proactive, and enhanced regulatory support to developers of promising medicines. It is designed to optimize development plans and accelerate evaluation, helping innovative therapies reach patients with unmet medical needs faster. Article content About BGB-16673 Article content BGB-16673 is an orally available Bruton's tyrosine kinase (BTK) targeting protein degrader from BeOne's chimeric degradation activation compound (CDAC) platform. BGB-16673 is designed to promote the degradation, or breakdown, of both wild-type and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease. BGB-16673 is the most advanced BTK protein degrader in the clinic, with an extensive global clinical development program. Article content About BeOne Medicines Article content BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Article content Forward-Looking Statement Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's advancement of, and anticipated clinical development, regulatory milestones and commercialization of BGB-16673; the potential of BGB-16673 to significantly address the unmet medical need; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. Article content Article content Article content Article content Contacts Article content Investor Contact Article content Article content Liza Heapes Article content Article content +1 857-302-5663 Article content Article content ir@ Article content Media Contact Article content Article content Kyle Blankenship Article content Article content Article content

Another Trump administration figure who met Laura Loomer's ire is out. A look at her influence
Another Trump administration figure who met Laura Loomer's ire is out. A look at her influence

Winnipeg Free Press

timea day ago

  • Winnipeg Free Press

Another Trump administration figure who met Laura Loomer's ire is out. A look at her influence

COLUMBIA, S.C. (AP) — President Donald Trump has downplayed the influence of Laura Loomer, a right-wing provocateur known for her incendiary social media presence, in his administration's decision-making. But the list of administration officials who have drawn Loomer's ire and swiftly thereafter gotten the ax from Trump has been growing. The latest was Dr. Vinay Prasad, the Food and Drug Administration's polarizing vaccine chief, who announced this week he was leaving the agency after a brief tenure that drew the ire of biotech executives, patient groups and conservative allies of Trump. Prasad had recently become a target of right-wing activists, including Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Sen. Bernie Sanders. Loomer, who has publicly encouraged Trump to purge aides who she believes are insufficiently loyal to the 'Make America Great Again' agenda, has taken credit for some of the ousters, tearing into some of Trump's allies and advisers and calling out what she calls a 'vetting crisis' within the White House. Trump, meanwhile, has long praised Loomer while distancing himself at times from her most controversial comments and downplaying her direct impact on his choices. Here's a rundown on connections between Loomer's criticism and Trump administration departures: Vocal opposition to Health and Human Services appointees Two people familiar with the situation told The Associated Press that Prasad was ousted following several recent controversies. The people spoke on condition of anonymity to discuss internal personnel matters. Last week, Loomer posted on X of Prasad, 'How did this Trump-hating Bernie Bro get into the Trump admin???' Prasad did not immediately respond to requests for comment Wednesday morning. He joined the FDA in May after years as an academic researcher at the University of California, San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. Loomer was also vocal in opposition to Trump's first choice for surgeon general, whose selection was ultimately withdrawn. Trump pulled the nomination of former Fox News medical contributor Janette Nesheiwat just before Senate confirmation hearings in May. Loomer had posted on X that 'we can't have a pro-COVID vaccine nepo appointee who is currently embroiled in a medical malpractice case and who didn't go to medical school in the US' as the surgeon general. Prompting departures at the National Security Council On April 3, Loomer presented 'research findings' to Trump, Vice President JD Vance, chief of staff Susie Wiles and others including then-national security adviser Mike Waltz, during an Oval Office meeting, according to people speaking on condition of anonymity to discuss personnel matters. A day later, Trump said he had fired 'some' White House National Security Council officials, downplaying Loomer's influence on the moves. The departures included the director of the National Security Agency, Air Force Gen. Tim Haugh, who also oversaw the Pentagon's Cyber Command, along with Haugh's civilian deputy at the NSA, Wendy Noble. When reached for comment, Loomer referred The Associated Press to an X post, saying she was not going to divulge any details about her Oval Office meeting with Trump 'out of respect' for the president. In a subsequent X post, Loomer appeared to take credit for the firings, writing, 'You know how you know the NSC officials I reported to President Trump are disloyal people who have played a role in sabotaging Donald Trump?' She noted, 'the fired officials' were being defended by Trump critics on CNN and MSNBC. Loomer called for Waltz's ouster in the weeks following revelations he had mistakenly added The Atlantic's editor-in-chief to a Signal chat being used to discuss military plans. As reports began to circulate that Waltz could be leaving the administration — he was ultimately nominated as United Nations ambassador — she appeared to take credit, writing 'SCALP' in an X post. A 'pressure campaign' targeting the Justice Department Adam Schleifer, an assistant U.S. attorney in Los Angeles, received an email in March saying he was being terminated 'on behalf of President Donald J. Trump,' according to a person familiar with the matter. The email came exactly an hour after Loomer called for him to be fired in a social media post that highlighted Schleifer's past critical comments about Trump while Schleifer was running in a Democratic primary for a congressional seat in New York. Earlier this month, Loomer took a victory lap after the Justice Department fired Maurene Comey, the daughter of former FBI director James Comey and a federal prosecutor in Manhattan who worked on the cases against Sean 'Diddy' Combs and Jeffrey Epstein, three people familiar with the matter told The AP. Comey's ouster, Loomer said on X, followed her two-month 'pressure campaign.' Has Loomer spoken out about others? Yes, chief among them Attorney General Pam Bondi. Loomer has called for Bondi's resignation over failure to keep promises to release more files from the Justice Department's sex trafficking investigation of Epstein, branding her a 'total liar.' Earlier this month, following DOJ's revelations that no Epstein 'client list' existed and no more files would be released, Loomer posted on X that she was told that FBI Deputy Director Dan Bongino was 'seriously thinking about resigning' amid his ongoing clashes with Bondi over the case. Weeks later, both Bondi and Bongino were still on the job. What has Trump said about Loomer's role? In April, Trump denied that Loomer had anything to do with aides being ousted from their jobs at the National Security Council, calling her a 'very good patriot and a very strong person' who only made recommendations. 'Sometimes I listen to those recommendations, like I do with everybody,' Trump said then, adding: 'She's usually very constructive. She recommended certain people for jobs.' Loomer was seen traveling with Trump during last year's campaign, accompanying him on a trip to New York and Pennsylvania as he commemorated the 9/11 attacks. She also traveled with Trump to Philadelphia for a debate against then-Vice President Kamala Harris. Loomer said she never officially joined the campaign after Trump's allies preferred he would keep his distance. After a Harris-related post on X in which Loomer played on racist stereotypes, Trump called Loomer 'a supporter of mine' with 'strong opinions,' but denied knowledge of her comments. He later posted on his Truth Social account that he disagreed with what she had said. ___ Kinnard can be reached at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store